Spotlight On... Gilead's hep C meds keep churning, but execs see need for deals as U.S. sales slow; Sun undercuts Novartis' Gleevec price by 30%; AZ's Tagrisso nabs quick EU approval; and more...

Gilead Sciences ($GILD) and its hep C juggernaut kept rolling in Q4, churning out street-beating sales of $4.9 billion. But it took strong growth overseas to overcome an expected falloff for Sovaldi and Harvoni in the U.S. While Gilead execs say there's lots of growth left in the hep C market, they acknowledged Tuesday that the company needs to be looking for M&A opportunities in areas such as oncology. Report

> Sun Pharmaceuticals discounted its new copycat version of Novartis' ($NVS) Gleevec by 30% to the brand, hoping to make big inroads in the market for leukemia treatments. Report

> AstraZeneca's ($AZN) Tagrisso (osimertinib) won expedited European approval for EGFR-positive advanced non-small cell lung cancer; it was approved by the U.S. FDA in November. Release

> China fined 5 domestic drugmakers almost 4 million yuan ($608,000) for price-fixing, saying they colluded to support the price of allopurinol, used to treat gout and kidney disease. Report

> The AIDS Healthcare Foundation sued Gilead Sciences ($GILD), accusing the company of holding back its next-gen TAF drug--now on its way to FDA approval--to allow a previous drug, tenofovir, to reap more sales. Report

And Finally... Teen girls with Type 1 diabetes are at higher risk of an eating disorder, with some skipping insulin doses to lose weight. Report

Suggested Articles

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.

The FDA wants to know what, exactly, is in a drug name—and whether it influences how the product is perceived. So it's launching a study to find out.

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.